KR20070110689A - Pharmaceutical composition comprising an extract of prunus persica l preventing from hepatotoxicity and nephrotoxicity induced by anticancer agent - Google Patents

Abstract

A pharmaceutical composition comprising the extract of Prunus persica L.(peach) for inhibiting hepatotoxicity and nephrotoxicity induced by an anticancer agent is provided to inhibit growth of cancer cells and increase anticancer effects with reducing side effects of cisplatin such as toxicity when the composition and cisplatin is simultaneously administered. A pharmaceutical composition for inhibiting hepatotoxicity and nephrotoxicity induced by an anticancer agent comprises 0.01-99 wt.%, preferably 0.02-50 wt.% of the extract of Prunus persica L. which is prepared by extracting Prunus persica L. with a solvent selected from water, C1-C4 lower alcohol or a mixed solvent thereof, wherein the Prunus persica L. is white peach or yellow peach; the daily dosage of Prunus persica L. extract is 0.0001-100 mg/kg, preferably 0.001-10 mg/kg; and the composition is formulated as tablet, pill, powder, granule, capsule, suspension, solution, emulsion or syrup.

Description

Pharmaceutical composition comprising an extract of Prunus persica L preventing from hepatotoxicity and nephrotoxicity induced by anticancer agent as an active ingredient having inhibitory activity against hepatotoxicity and renal toxicity induced by anticancer agents

1 shows the effect of peach extract on weight loss of liver and kidney when high concentrations of cisplatin (45 mg / kg body weight) was administered in ICR mice to induce hepatotoxicity and renal toxicity (†; P <0.001 Significance with control, *; P <0.05, **; P <0.01, ***; P <0.001 indicates significance with cisplatin only group, group I control, group II cisplatin 45 mg / kg Weight, Group III: 500 mg / kg white pulpy flesh + cisplatin 45 mg / kg Weight, Group IV: 500 mg / kg of white peach pulp + cisplatin 45 mg / kg Weight, Group V: zodiacal flesh 500 mg / kg weight + cisplatin 45 mg / kg body weight, group VI represents ecliptic rind 500 mg / kg body weight + cisplatin 45 mg / kg body weight)

Figure 2 shows the tumor growth after administration of low concentrations of cisplatin (5 mg / kg) and peach extract (500 mg / kg) in 15 days subcutaneously injected with CT-26 mouse colon cancer cells (BALB / c mice) (#; P <0.0005, ##; P <0.00005 indicates significance with subcutaneous injection of CT-26 cells only, tumor volume = (length × width ² ) / 2, Group I is the control group, Group II is CT-26 cells, Group III is CT-26 cells + cisplatin 5 mg / kg weight, Group IV is CT-26 cells + white pulpy flesh 500 mg / kg, Group V CT-26 cells + ecliptic pulp 500 mg / kg weight, group VI shows CT-26 cells + white peach pulp + cisplatin, group VII CT-26 cells + ecliptic pulp + cisplatin administration group)

Figure 3 shows the peach extract of the liver and kidney weight changes when hepatotoxicity and renal toxicity were induced by low concentrations of cisplatin administration to white mice (BALB / c mice) injected subcutaneously with CT-26 mouse colon cancer cells. (<; P <0.005, ##; P <0.0001 is significant with the subcutaneous injection of CT-26 cells, *; P <0.05, **; P <0.01, ***; P <0.005 indicates significance with cisplatin only group, group I is control group, group II is CT-26 cells, group III is CT-26 cells + cisplatin 5 mg / kg body weight, group IV is CT-26 cells + White pulmonary pulp 500 mg / kg weight, group Ⅴ weight CT-26 cells + zodiacal pulp 500 mg / kg weight, group Ⅵ CT-26 cells + white peach pulp + cisplatin, group CT CT-26 cells + zodiacal pulp + cisplatin Each of the administration groups)

The present invention relates to medicines and health functional foods that white and peach peach extracts suppress liver and kidney toxicity by cisplatin while enhancing anticancer efficacy of cisplatin when cisplatin anticancer agent is administered.

Cancer is a disease that causes about 7 million deaths per year worldwide. Especially in Korea, according to the Statistical Yearbook of Cause of Death of 2000 (analysis of 2000 death data), death from cancer 23.5% is the number one cause of death, and national cancer management measures are required. Currently, various methods such as surgery, radiation therapy, and gene therapy are used to treat cancer, but one of the most used treatments is chemotherapy, in which anticancer drugs are administered.

Chemotherapy is a systemic treatment, most of which is given by injection or oral anticancer drugs and spreads throughout the bloodstream. Therefore, it is a treatment that acts on the microcommitment (micometastasis) spread throughout the body rather than a local effect. Therefore, there are many systemic side effects and the degree is very severe compared to surgery or radiation therapy. The use of drug-sensitivity differences between normal cells and cancer cells to allow chemotherapy to act selectively on cancer cells results in dose-limiting toxicity because chemotherapy or most anticancer drugs do not distinguish between normal and cancer cells. There is a problem.

Cis-diammine-dichloroplatinum [II], a representative anticancer agent, is widely used in clinic as a chemotherapeutic agent for the treatment of ovarian cancer, bladder cancer, lung cancer, head and neck cancer, testicular cancer (Rosenberg B., Cancer , 55 : pp2303-). 2315, 1985). Cisplatin is known to have anti-cancer effects by producing active oxygen species to attack cancer cells, inducing inter-intrastrand cross-linking of DNA, and formation of DNA adducts. However, side effects such as hearing loss, neurotoxicity, and kidney toxicity are observed above the limited amount of drug during treatment (Mollman et al., 1998; Screnci and McKeage , 1999), and hepatotoxicity is also frequently associated with high concentrations of cisplatin. (Cerosimo R. J., Ann. Pharm ., 27 : pp 438-441, 1993; Cavalli F. et al., Cancer Treat. Rep., 62 : pp 2125-2126, 1978; Pollera CF et al., J. Clin . Oncol ., 5 : pp318-319, 1987). These side effects with cisplatin are caused by increased lipid peroxidation due to reactive oxygen species produced by cisplatin (Matsushima H. et al., J. Lab. Clin. Med ., 131 : pp518-526, 1998; Koc A. et al. , Mol . Cell Biochem . , 278 (1-2) : pp79-84, 2005), inhibition of antioxidant enzyme activity present in tissues (Sadzuka Y. et al., Biochem . Pharmacol ., 43 : pp1873-1875, 1992), depletion of glutathione (Zhang JG and Lindup WE, Biochem . Pharmcol. , 45 : pp2215-2222, 1993) and disruption of intracellular calcium homeostasis (Zhang JG and Lindup WE, Toxicology in Vitro , 10 : pp205209, 1996).

It has been recently observed that cisplatin and glutathione esters effectively suppress the renal toxicity caused by cisplatin (Babu E. et al., Mol. Cell Biochem ., 144 : pp7-11, 1995). Much attention has been focused on suppressing cisplatin-induced toxicity by ingesting antioxidants from diet (Appenroth D. et al., Arch. Toxicol . , 71 : pp677-683, 1997; Bogin E. et al., Eur ... J. Clin Chem Clin Biochem , 32: pp843-851, 1994; Rao M. et al, J. Biochem, 125:.... pp383-390, 1999).

Many chemotherapeutic agents, including cisplatin, are known to produce free radical species and attack cancer cells, and the produced free radical species are known to act on normal cells and cause damage. Thus, substances with antioxidant effects are likely to reduce the toxicity caused by chemotherapeutic agents. In addition, hepatic toxicity and renal toxicity caused by external harmful substances generating reactive oxygen species or radicals can be effectively suppressed.

Prunus persica L) is a fruit belonging to the family Rosaceae, and its origin is China. Currently, peaches are widely used for raw food, but they are also used as ingredients for processed foods such as sake, juice, alcohol, and canned food. The pulp contains nutrition, organic acids, minerals, vitamins, enzymes, etc. as a seasonal fruit. In addition, peaches have a unique fruit flavor and are widely used in various food products. The plant fiber content is 2.3-2.7% in total skin. Plant fiber is known to be effective in preventing cancer and inhibiting the growth of harmful bacteria by removing the wastes in the body and reducing the residence time of carcinogens and toxins by activating the bowel movements.

Peach's astringent taste is due to polyphenols such as catechin, proanthocyanin, and chlorogenic acid. Polyphenols have excellent antioxidant effects (Chun OK, et al. , J Agric Food Chem . , 51 : pp8067-8072, 2003;: Proteggente AR, et al., Free Radic Res. , 36: pp217-233, 2002), carcinogenesis caused by the reaction of nitrous acid with amine compounds It has the effect of inhibiting the production of nitrosoamine (nitrosoamine).

Reported to date, extracts of peach blossoms are known to inhibit UV damage-induced DNA damage and skin carcinogenesis (Heo MY, et al., Mutat Res., 496 : pp47-59, 2001). In addition, glycoside glycosides have been reported to have antitumor effects (Yoshida T., et al., Biol. Pharm . Bull. 26 : pp271-173, 2003).

Therefore, the present inventors confirmed that white and peach peach extract inhibited liver toxicity and kidney toxicity by cisplatin while enhancing the anticancer efficacy of cisplatin when cisplatin was administered, and exhibited anticancer efficacy comparable to cisplatin even when only peach extract was administered. It was confirmed that the present invention was completed.

The present invention is for the prevention and treatment of hepatotoxicity and renal toxic diseases containing peach extracts as an active ingredient that inhibits liver toxicity and renal toxicity by anticancer agents such as cisplatin while enhancing the anticancer efficacy of cisplatin and the like upon administration of anticancer agents such as cisplatin. It is an object to provide a pharmaceutical composition.

In order to achieve the above object, the present invention provides a pharmaceutical composition for the prevention and treatment of liver and kidney toxicity diseases caused by an anticancer agent comprising a peach extract as an active ingredient.

The present invention provides an anticancer adjuvant comprising a peach extract having an inhibitory activity against liver toxicity and kidney toxicity induced by an anticancer agent as an active ingredient.

The extract comprises extracts soluble from water, lower alcohols having 1 to 4 carbon atoms or mixed solvents thereof, preferably ethanol.

The anticancer adjuvant is administered in combination with existing anticancer agents such as cisplatin, carboplatin, oxaliplatin, nedaplatin, doxorubicin, taxol, tamoxyphene, camptobel, adresyl, glibeck, etoposide, zometa, and oncobin. Can promote it.

Peach as defined herein includes pulp and rind of peaches, such as zodiacal and white peach.

Hereinafter, the present invention will be described in detail.

Prunus of the present invention persica L) extract is a solvent selected from about 1 to 20 times, preferably about 3 to 12 times water, C ₁ to C ₄ lower alcohols or a mixed solvent thereof, of about 1 to 20 times the weight of the dry sample (kg). Preferably ethanol cold extraction, hot water extraction, instrument extraction, ultrasonic extraction, reflux cooling extraction for 0 to 100 ℃, preferably 10 to 50 ℃ extraction temperature for about 12 hours to 5 days, preferably 1 to 3 days Extraction method such as extraction, preferably by reflux extraction several times, and additionally concentrated under reduced pressure at a temperature of 10 to 100 ℃ preferably 30 to 70 ℃ to obtain the peach extract of the present invention.

The present invention provides a pharmaceutical composition for the prevention and treatment of hepatotoxicity and renal toxic diseases caused by an anticancer agent containing the peach extract obtained by the above method as an active ingredient.

The pharmaceutical composition of the present invention preferably contains 0.01 to 99% of the peach extract, more preferably 0.02 to 50%. The above content does not limit the scope of the present invention in any aspect.

The present invention comprises a peach extract having an inhibitory activity against hepatotoxicity and renal toxicity caused by an anticancer agent as an active ingredient, and the prevention of hepatotoxicity and renal toxic diseases, including a pharmaceutically acceptable carrier, diluent or excipient, and It provides a therapeutic pharmaceutical composition.

The pharmaceutical composition comprising the peach extract of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.

Pharmaceutical dosage forms of the peach extract of the present invention may be used in the form of their pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active compounds as well as in a suitable collection.

Pharmaceutical compositions comprising peach extracts according to the present invention are in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories, and sterile injectable solutions, respectively, according to conventional methods. Can be formulated and used. Carriers, excipients and diluents that may be included in the composition comprising the compound include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate, sucrose ( It is prepared by mixing sucrose or lactose and gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

Preferred dosages of the peach extract of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the desired effect, the compound of the present invention is preferably administered at 0.0001 to 100 mg / kg, preferably at 0.001 to 10 mg / kg. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.

Peach extract of the present invention can be administered to a variety of routes to mammals, such as mice, mice, livestock, humans. All modes of administration can be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intra-cerebroventricular injections.

The present invention provides a dietary supplement for the prevention and improvement of liver and kidney toxicity diseases caused by an anticancer agent including a peach extract and a food acceptable food additive. Examples of the food to which the peach extract of the present invention can be added include various foods, beverages, gums, teas, vitamin complexes, and health functional foods.

As defined herein, "health functional food" means a food manufactured and processed using raw materials or ingredients having functional properties useful for the human body according to Act No. 6767 of the Health Functional Food Act, and "functional" means It means ingestion for the purpose of obtaining useful effects on health use such as nutrient control or physiological action on structure and function.

It may also be added to foods or beverages for the purpose of preventing the liver and kidney toxic diseases caused by anticancer agents. At this time, the amount of the extract in the food or beverage may be added at 0.01 to 15% by weight of the total food weight, the health beverage composition is based on 100 ml in a ratio of 0.02 to 5 g, preferably 0.3 to 1 g Can be added.

Health functional food of the present invention includes the form of tablets, capsules, pills, liquids and the like.

For example, the health functional food in the form of tablets may be prepared as it is or granularly mixed with an excipient, a binder, a disintegrating agent or other additives in a suitable manner, and then compressed into a glidant, etc. It is made by directly compressing the functional food as it is or by mixing it evenly with an excipient, binder, disintegrant or other suitable additives, or mixing the health functional food as it is or evenly adding the appropriate additive to the prepared granules, The excipient, binder or other suitable additives are added to the functional food, and the powder mixed evenly is wetted with a solvent, the wet powder is molded into a mold at low pressure, and then dried and prepared by a suitable method. In addition, the nutraceutical can be added to the health functional food in the form of tablets, if necessary, can be avoided with a suitable epidermis.

Among the health functional foods in the form of capsules, the hard capsules are usually prepared by mixing the capsules evenly with the health functional foods or excipients suitable for the health functional foods, granulated by a suitable method, or granulated with a suitable epidermal agent as it is or Soft capsules are prepared by filling them, and soft capsules are usually filled with capsules containing glycerin or sorbitol in a capsule form containing gelatin or appropriate excipients suitable for health functional foods or health functional foods. It is molded and prepared, and a coloring agent preservative etc. can be added to the said capsule base as needed.

Circular functional foods are usually mixed with excipients, binders, disintegrants, etc., and then molded into a spherical form in a suitable manner, and the coating is carried out with white sugar or other suitable coating agent, or starch, talc or You can also be greeted with a suitable substance.

The health functional food in the form of granules is usually made by mixing the health functional food as it is or by adding excipients, binders, disintegrating agents, etc., evenly and then granulating it in a proper way to make the particles as even as possible. , Mating agent, etc. can be added. For the health functional food in the form of granules, No. 12 (1680 μm), No. 14 (1410 μm) and No. 45 (350 μm) were used for the next particle size test. It should be less than 5.0% and pass through No.45 to less than 15.0% of the total amount.

The definitions of the excipients, binders, disintegrants, lubricants, copulation agents, flavoring agents, etc. of the present invention are those described in the literature known in the art and include those having the same or similar functions. , Korean College of Pharmacy, 5th Edition, p33-48, 1989).

The health functional beverage composition of the present invention is not particularly limited to other ingredients except for containing the peach extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. . Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of said natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.

In addition to the above, the peach extract of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, alginic acid and Salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like. In addition, the compounds of the present invention may contain flesh for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is usually selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the compound of the present invention.

Since the peach extract of the present invention has little toxicity and side effects, it can be used with confidence even for long-term use for the purpose of prevention.

Hereinafter, the present invention will be described in detail by the following Examples and Experimental Examples. However, the following Examples and Experimental Examples are merely illustrative of the present invention, and the content of the present invention is not limited by the following Examples and Experimental Examples.

Example  1. Preparation of Peach Extract

Baekdo and zodiacal peaches used in the present invention were purchased at 100 kg each in the eastern orchards of Gyeonggi-do Janghowon Gyeonggi. Seeds were removed, the flesh and skin were separated, and each was cut and lyophilized. 80% ethanol was added at a ratio of 1: 5 (w / v) to the dry flesh and skin, respectively, and the mixture was extracted three times under reflux for 48 hours at room temperature. The extract was filtered using Filtration No. 2 (Advantec TOYO, JAPAN), concentrated under reduced pressure with a rotary vacuum evaporator (Heidolph VV2011, Switzerland) at 50 ° C., and then lyophilized to yield white peach pulp extract (14.05 g) and white peach pulp extract. (13.60g), zodiacal pulp extract (13.96g) and zodiacal rind extract (13.75g) were obtained, which were stored at -20 ° C and used as a sample for the following experiment.

Experimental Example  One. In mice  High concentration Cisplatin  Inhibitory Effects of Peach Extracts on Hepatotoxicity and Renal Toxicity Induced by Administration

1-1. With cisplatin  Causes liver and kidney toxicity

Eight mice (5 weeks old, males) were used per experimental group. Mice were orally administered with peach extract dissolved in phosphate buffer (phosphate-buffered saline, PBS) as shown in Table 1 for 7 days. Three hours after the last dose of peach extract, cisplatin dissolved in PBS was intraperitoneally injected at a dose of 45 mg (45 mg / kg body weight) per kg body weight of the mouse. In the negative control group, PBS was administered instead of peach extract and cisplatin, and cisplatin, a positive control group, was administered orally with PBS for 7 days instead of peach extract, followed by cisplatin. Sixteen hours after cisplatin administration, body weights were measured, mice were anesthetized with ether, and blood was collected from the heart to examine biochemical markers related to liver and kidney toxicity. The liver and kidney were separated and the weight of each organ was measured, and the percentage of liver and kidney to the mouse weight was calculated, respectively.

Administration method and dose of cisplatin and peach extract Experimental group Oral administration (7 days) Intraperitoneal injection (16 hours) Control group (group I) PBS PBS Cisplatin Administration Group (Group II) PBS Cisplatin (45mg / kg BW) White peach pulp + cisplatin-treated group (Group III) White peach pulp extract (500mg / kg BW) Cisplatin (45mg / kg BW) White peach skin + cisplatin administration group (Group IV) White peach rind extract (500mg / kg BW) Cisplatin (45mg / kg BW) Zodiacal pulp + cisplatin-treated group (group Ⅴ) Zodiacal pulp extract (500mg / kg BW) Cisplatin (45mg / kg BW) Zodiacal rind + cisplatin-treated group (Group Ⅵ) Ecliptic Skin Extract (500mg / kg BW) Cisplatin (45mg / kg BW) BW: body weight PBS: phosphate-buffered saline

1-2. Liver and Kidney Shredding Preparation

The extracted liver and kidneys were rapidly washed with refrigerated 1.15% potassium chloride (KCl) buffer solution to remove blood, and then maximally dehydrated with a damp paper. Immediately after removal of water, add potassium chloride (KCl) buffer solution to 10% (w / v%) in liver and kidneys, and then to tissue homogenizer (IKA-WERKE, T8, Homogenizer, Germany) in ice bath. Crushed to make liver tissue and kidney tissue homogenate. Each homogenate was centrifuged at 2,000 rpm for 10 minutes, and the supernatant was taken in a predetermined amount to prepare a liver tissue fraction and a kidney tissue fraction, which were used to measure the content of lipid peroxide (LPO) and GSH.

1-3. Preparation of Blood Samples

Blood collected from the heart was centrifuged at 3,000 rpm and 4 ° C. for 10 minutes to obtain serum. Nitric oxide was immediately determined using the collected serum, and AST (aspartate aminotransferase), ALT (alanine aminotransferase), blood urea nitrogen and creatinine were quantified within at least 24 hours.

1-4. Determination of Nitric Oxide

There are free radicals in the living body, such as nitric oxide (NO), which are always produced in small, constant concentrations to maintain physiological functions. In the early stages of infectious disease, stress and tumorigenesis, various immune cells for host defense are activated, producing excess nitric oxide free radicals. Nitrogen monoxide thus formed protects the living body by attacking infectious bacteria such as viruses, bacteria and parasites or by destroying tumor cells at an early stage of cancer cell formation. However, when an excessive amount of free radicals are produced for a long time, the function of normal cells is destroyed, which causes chronic diseases. These free radicals inactivate intracellular substances such as proteins, lipids, nucleic acids, and amino acids, which are important for the normal functioning of the human body, eventually becoming a fundamental cause of various diseases. This over-produced nitrogen monoxide is a radical ^- in combination with nitrogen peroxide (ONOO ^-) (O ₂₎ is generated by another toxic substance, such as when a complex free radical toxicity. Therefore, the content of nitric oxide was quantified by the following method.

The content of oxidized nitrogen is contained in the serum nitrite (nitrite, NO ^{2 -)} and nitrates (nitrate, NO ^{3 -).} Amount was measured by using a grease (Griess) solution (Cortas NK and Wakid NW, Clin Chem in. , 36 : pp1440-1443, 1990).

As a standard solution, sodium nitrite (NaNO ₂ ) solution was prepared at 250, 125, 62, 31, 15, and 7 μM, and 100 μl each was put into a 96 well plate, and the serum obtained from each experimental group was diluted twice to 100. ΜL was added to a 96 well plate. The grease solution is mixed with 0.2% naphthylethylenediamine dihydrochloride and 2% sulfonylamide in a 1: 1 solution just before use, so that each well with standard solution and serum 100 μl each was added. After reacting for 5 minutes at room temperature, the absorbance was measured at 540 nm using an ELISA reader (Belmark, Bio-Rad, USA). Nitrogen oxide content was quantified using a standard curve.

1-5. AST ( aspartate aminotransferase ) And ALT ( alanine aminotransferase Quantification of

Aminotransferase is an enzyme that is abundant in the liver and is normally detected in the blood in a very small amount, but is detected in a large amount in the blood of patients with liver disease, which is a useful indicator for measuring liver toxicity. Quantification was as follows.

Pyruvic acid is formed during the reaction of alanine + α-ketoglutaric acid → pyruvic acid + glutamic acid (alanine + α-ketoglutaric acid → pyruvic acid + glutamic acid) by ALT enzyme, and aspartate + α by AST enzyme Oxaloacetate formed during the reaction of ketoglutaric acid → oxaloacetate + glutamic acid (aspartate + α-ketoglutaric acid → oxaloacetate + gluatmic acid) is unstable and is converted into pyruvate immediately upon production. The content of ALT and AST was measured by absorbance at 505 nm for the degree of color produced by reacting pyruvic acid produced by ALT and AST with 2,4-dinitrophenylhydrazine. (Reitman S. and Frankel S., A m. J Clin . Patho l., Jul; 28 (1) : pp56-63, 1957). ALT and AST measurement kit (kit) was quantified using the product of Asan Pharmaceutical (Korea), and hemolytic serum was higher than ALT and AST enzyme than normal serum.

1 ml of alanine-α-keto glutamic acid substrate was added to a 15 ml conical-tube and warmed in an oven at 37 ° C. for 5 minutes. 0.2 ml of the test serum was added to each tube and reacted in a 37 ° C. water bath for 30 minutes. Then, 1 ml of a coloring solution (2,4-dinitrophenylhydrazine) was added thereto and left at room temperature for 20 minutes. 10 ml of 0.4N sodium hydroxide (NaOH) solution was added to each tube, and the reaction was stopped by sufficiently mixing. The absorbance was read at 505 nm with distilled water as a blank to investigate the activity of the ALT enzyme. AST activity was added to 1 ml of aspartate-α-keto glutamic acid substrate and warmed for 5 minutes in a 37 ℃ oven. 0.2 ml of the test serum was added to each tube, and the reaction was carried out for 60 minutes in a 37 ° C. water bath, and the absorbance was measured at 505 nm by the same method as in the ALT. A calibration standard curve was prepared using pyrubic acid lithium to quantify the ALT and AST contents of the test serum.

1-6. Blood Of urea nitrogen  dose

Urea ((NH ₂ ) ₂ CO) is a major end-product of protein and amino acid metabolism that is produced in the liver, travels through the blood to the kidneys, and is excreted in the urine. Therefore, when kidney function deteriorated, urea was not filtered and excreted in the kidney, so blood urea content was increased, and blood urea nitrogen was an indicator for evaluating kidney function.

The content of urea nitrogen in blood was measured using the Urease-Indophenol method (Uchida K. and Tejima K., Rinsho Byori ., Oct ; 22 : p207.1974). Absorbance at 580 nm was measured at 580 nm through a color reaction of ammonia (NH ₃ ) produced during hydrolyze of urea using a kit for measuring blood urea nitrogen (Asan Pharmaceutical, Korea). It was.

2 ml of urease solution was added to a 15 ml conical tube, 20 μl of test serum was mixed well, and then reacted in an oven at 37 ° C. for 5 minutes. 2 ml of a color reagent (NaOCl) solution was mixed into each tube and absorbance was measured at 580 nm. The urea nitrogen content of the test serum was calculated using 30 mg / dL of urea nitrogen as a standard reagent and distilled water as a blank.

1-7. Creatinine ( creatinine Quantification of

After protein is used as an energy source in muscle, creatine is produced and creatine is broken down to produce creatinine. Creatinine is excreted in the blood, then filtered by the kidneys and excreted in the urine. Since creatinine in the blood is always constant and changes only by renal function, which is an important indicator for renal function, creatinine was quantified as follows.

The content of creatinine was measured using the Jaffe method (Jaffe method; Taussky HH., Clin . Chim . Acta . May-Jun ; 1 (3) : pp210-224, 1956). The yellow color reaction of creatinine reacted with picric acid was measured at 520 nm, and the absorbance was measured using a creatinine measurement kit (Asan Pharmaceutical, Korea) that minimized interference with chromogen in serum.

4 ml of the protein whitening solution in the kit and 100 µl of the test serum diluted five-fold were mixed well, and allowed to stand at room temperature for 20 minutes, followed by centrifugation at 3,000 rpm for 10 minutes. 3 ml of the supernatant was transferred to a tube, 1 ml of 0.4 N NaOH solution was added thereto, and the mixture was left at room temperature for 20 minutes, and the absorbance was measured at 520 nm. The amount of creatinine in the test serum was calculated using 5 mg / dL of creatinine as the standard solution.

1-8. Lipid peroxide ( lipidperoxide Quantification of

Lipid peroxidation occurs when unsaturated fatty acids are exposed to oxygen. Lipid peroxidation is initiated by deodorizing hydrogen atoms (H ·) from methylene (—CH ₂ —) groups of unsaturated fatty acids by free radicals. Biofilms contain large amounts of unsaturated fatty acids, so that structural changes in lipid molecules due to lipid peroxidation occur over a wide range, resulting in reduced biofilm fluidity, reduced membrane potential, increased ion permeability, and increased organelle content. Leakage occurs and eventually leads to a decrease in cell function and cell death. Lipid peroxides and their degradation products are harmful to the body, and harmful actions have been reported such as inhibition of macrophage function, inhibition of protein synthesis, inactivation of enzymes, and thrombin overproduction (Halliwell, B., Gutteridge, JM and Blake D., Philos. Trans . R Soc Lond B Biol Sci . Dec 17; 311 (1152) : pp659-671. 1985). Degradation products of lipid peroxides include many kinds of carbonyl compounds. The representative substance is malondialdehyde (MDA), which is used to evaluate thiobarbituric acid (TBA) reaction to evaluate the degree of lipid peroxidation. Since it can detect through, the amount of lipid peroxide was quantified as follows.

The MDA content of lipid peroxide (LPO) in the liver tissue homogenate was measured by thiobarbituric acid method (Ohkawa H. et al., Analytical Biochem. 95 : pp351-358. 1978). To 200 μl of liver tissue homogenate, 0.2 ml of 8.1% SDS, 1.5 ml of 20% acetic acid solution (pH 3.5), 1.5 ml of 0.8% TBA solution and 0.6 ml of distilled water were added, followed by 60 minutes in a 95 ° C. constant temperature water bath. After heating, the mixture was cooled to room temperature, and 5 ml of a mixture of 1 ml of distilled water and n-butanol: pyridine (15: 1, v / v) was added and mixed vigorously. The mixture was centrifuged at 4,000 rpm for 10 minutes to separate the n-butanol layer in which the TBA reactant was present, and the absorbance was measured at 532 nm. The content of LPO was prepared using a standard calibration curve using tetramethoxypropane, and then the amount of malondialdehyde in the test serum was calculated.

1-9. Of glutathione  dose

GSH (glutathione) has a function of reacting directly when external toxic substances invade into cells or by binding to toxic substances by GST (glutathione- S- transferase). GST is known to have detoxification by using electrophilic foreign substances as substrates and by conjugating glutathione to it and finally excreting it in urine. Therefore, depletion of GSH in tissues is known to increase toxicity, particularly hepatotoxicity, so glutathione was quantified as follows.

The content of glutathione (GSH) was quantified using the method of Higach (Higach T., Nucleic Acid and Enzyme. 33 : p1370. 1988). An equal amount of 10% trichloroacetic acid solution was added to 10% liver tissue homogenate, centrifuged at 3,000 rpm for 20 minutes, and the supernatant was taken. 0.01 M nitrite-0.2N sulfuric acid (0.01 M NaNO ₂ -0.2NH ₂ SO _{4 in} 0.1 ml of supernatant) = 1: 9, v / v) 0.5 ml of liquid mixture was added, and it left to stand for 5 minutes. 0.2 ml of 0.5% aqueous sulfamic acid ammonium solution was added and mixed vigorously, followed by mixing 1% mercury chloride (HgCl ₂ ) and 3.4% sulfanamide / 0.4N hydrochloric acid (sulfanilamide / 0.4N HCl mixture = 1). 9, v / v) was added 1 ml each, and again 1 ml of 0.4N hydrochloric acid (HCl) solution containing 0.1% N-1-naphthyl ethyl enediamine was added. After 5 minutes, absorbance at 540 nm was measured. A calibration standard curve was prepared using the GSH standard, and the amount of GSH in the test serum was calculated using this.

1-10. Statistical processing

The experimental results are expressed as the average value ± SE. Statistical analyzes Student's t - test was used (Student t -test). P value (P value) is 0.05 or less were evaluated as having significance.

1-11. Experiment result

In the cisplatin-administered group, which was intraperitoneally injected with cisplatin at a dose of 45 mg / kg, the weight of liver and kidney was reduced compared to the control group, but the peach extract was first administered at a dose of 500 mg / kg for 7 days and then in the cisplatin-treated group. Liver and kidney weights returned to nearly normal levels (see FIG. 1 and Tables 2 and 3).

In the cisplatin-treated group injected with cisplatin at 45 mg / kg, hepatic damage increased the levels of nitric oxide, AST and ALT enzymes in the blood, increased MDA in tissues, and depletion of GSH. In the group of 500 mg / kg peach extract administered orally for 7 days prior to the intraperitoneal injection, all of the contents of nitric oxide, AST and ALT in blood were significantly decreased compared to those of cisplatin alone, and the formation of lipid peroxides in tissues And depletion of GSH was inhibited (see Table 2).

Protective Effect of Peach Extract on Cisplatin-induced Liver Toxicity Control Cisplatin (45mg / kg BW) Cisplatin (45 mg / kg BW) White peach White peach Zodiacal flesh Zodiacal rind group I Ⅱ Ⅲ Ⅳ Ⅴ Ⅵ L.W / BW (%) 10.3 ± 0.1 8.3 ± 0.2 ^### 9.5 ± 0.4 ^* 9.8 ± 0.14 ^** 10.2 ± 0.2 ^*** 10.2 ± 0.4 ^** Nitric Oxide (μM) 6.7 ± 0.9 26.6 ± 2.9 ^### 13.5 ± 1.5 ^* 11.9 ± 1.1 ^** 10.1 ± 1.6 ^** 12.2 ± 1.8 ^** AST (U / L) 139.8 ± 3.1 268.8 ± 34.6 ^# 148.0 ± 16.3 ^* 155.4 ± 26.9 ^* 164.8 ± 6.7 ^* 153.5 ± 13.7 ^* ALT (U / L) 44.3 ± 5.5 221.1 ± 20.5 ^### 55.3 ± 10.2 ^*** 60.6 ± 4.1 ^*** 60.9 ± 13.5 ^*** 64.4 ± 6.3 ^*** MDA (nmol / mg) 1.4 ± 0.2 6.5 ± 0.7 ^## 1.9 ± 0.4 ^** 1.5 ± 0.1 ^*** 1.8 ± 0.3 ^** 1.4 ± 0.2 ^*** GSH (nmol / mg) 15.6 ± 0.5 7.8 ± 0.5 ^## 14.9 ± 0.9 ^** 13.7 ± 1.1 ^** 12.7 ± 0.9 ^** 13.8 ± 1.3 ^** L.W (liver weight) / BW (body weight): Percentage of liver tissue weight to mouse weight #P; <0.01, ## P; <0.001, ### P; <0.0001 indicates significance * P with control; <0.05, ** P; <0.005, *** P; <0.0005 is significant with cisplatin-treated group

In the cisplatin-administered group injected with cisplatin at 45 mg / kg, the increase of urea nitrogen and creatinine in the blood and the increase of MDA in the tissue were observed due to kidney damage, whereas 500 mg of peach extract was injected orally for 7 days before intraperitoneal injection of cisplatin. In the group administered at the / kg dose, both urea nitrogen and creatinine contents were significantly reduced and the formation of lipid peroxides in the tissues was suppressed compared with the cisplatin-only group (see Table 3).

Therefore, it was confirmed that the peach extract significantly inhibited liver toxicity and kidney toxicity caused by cisplatin administration.

Protective Effect of Peach Extract on Cisplatin-Induced Kidney Toxicity Control Cisplatin (45mg / kg BW) Cisplatin (45 mg / kg BW) White peach White peach Zodiacal flesh Zodiacal rind group I Ⅱ Ⅲ Ⅳ Ⅴ Ⅵ K.W / BW (%) 2.5 ± 0.1 1.9 ± 0.1 ^# 2.4 ± 0.1 ^* 2.4 ± 0.04 ^** 2.3 ± 0.1 ^** 2.3 ± 0.03 ^** BUN (mg / ㎗) 12.3 ± 0.3 45.3 ± 1.2 ^## 13.6 ± 0.6 ^*** 13.1 ± 0.9 ^*** 12.4 ± 0.5 ^*** 14.1 ± 0.5 ^*** Creatinine (mg / dl) 3.3 ± 0.1 6.6 ± 0.3 ^# 4.1 ± 0.1 ^*** 4.1 ± 0.1 ^*** 4.1 ± 0.1 ^*** 4.3 ± 0.1 ^** MDA (nmol / mg) 2.4 ± 0.4 10.7 ± 0.9 ^# 3.7 ± 0.6 ^*** 2.6 ± 0.2 ^*** 3.8 ± 0.5 ^*** 3.9 ± 0.8 ^*** K.W (renal weight) / BW (body weight): Percentage of kidney tissue weight to mouse weight #P; <0.0005, ## P; <0.00001 indicates significance * P with control; <0.05, ** P; <0.001, *** P; <0.0005 is significant with cisplatin-treated group

Experimental Example  2. CT-26 cells injected with mouse colon cancer cell line In mice  Inhibitory Effects of Cisplatin and Peach Extracts on Tumor Formation

2-1. Tumor formation

Eight white mice (BALB / c mice; 5 weeks old, males) were used per experimental group. After CT-26 cancer cells (2 × 10 ⁷ cells / ml) were suspended in PBS, 100 μl (2 × 10 ⁶ cells) were injected subcutaneously (subcutaneous) of mice. Twenty four hours after injecting the cancer cells, 100 μl (500 mg / kg body weight) of the peach extract dissolved in PBS was orally administered, and 100 μl of cisplatin (5 mg / kg body weight) was intraperitoneally administered 2 hours after the oral administration of the peach extract. Tumor size was measured while peach extract and cisplatin were administered daily in the same manner for 15 days. Table 4 shows the administration method, duration and dose of cisplatin and peach extract.

2-2. Generated tumor size measurement method and tumor volume calculation method

After 7 days after the cancer cells were injected, if the tumor grew to a visible level, the hairs near the tumor were removed and the length (L) and width (W) of the tumor were measured using a vernier caliper. Tumor volume was calculated by the following equation (Rene C.-Gaudreault, et al., Can. Res. , 64 , pp4654-4663, 2004). (See Figure 2 and Table 5).

Administration method, duration and dose of cisplatin and peach extract Experimental group Oral administration (15 days) Intraperitoneal administration (15 days) Control group (Group I) PBS PBS CT-26 Mouse Colon Cancer Cell Infusion Group (Group II) PBS PBS CT-26 Cancer Cell Injection Cisplatin Administration Group (Group III) PBS Cisplatin (5mg / kg BW) White peach pulp extract group (Group IV) White peach pulp extract (500mg / kg BW) PBS Zodiac pulp extract group (Group Ⅴ) Zodiacal pulp extract (500mg / kg BW) PBS White peach pulp + cisplatin group (group Ⅵ) White peach pulp extract (500mg / kg BW) Cisplatin a (5mg / kg BW) Zodiacal pulp + cisplatin-treated group (group Ⅶ) Zodiacal pulp extract (500mg / kg BW) Cisplatin (5mg / kg BW) BW: body weight PBS: phosphate-buffered saline

Tumor growth was inhibited by 57.3% in the daily administration of cisplatin 5mg / kg after cancer cell injection compared to the CT-26 mouse colon cancer cell injection group. Was inhibited. After cancer cell injection, 51.9% of the nectar extracts and 47.9% of the nectar extracts were observed. Tumor growth inhibitory effect of 68.4% was observed in the group treated with cisplatin and white peach pulp extract, and 71.6% in the group treated with zodiacal pulp extract. Higher (see Table 5 and FIG. 2).

Therefore, white and yellow peach extracts themselves showed anticancer efficacy similar to cisplatin, and when the peach extracts were administered with cisplatin, it was confirmed that the anticancer efficacy of cisplatin was increased.

Anticancer Effects of Cisplatin and Peach Extracts in White Mice (BALB / c Mice) Control CT-26 cell subcutaneous injection group CT-26 Cell Subcutaneous Injection Cisplatin (5mg / kg BW) White peach pulp (500mg / kg BW) Ecliptic pulp (500mg / kg BW) Cisplatin (5mg / kg BW) White peach pulp (500mg / kg BW) Ecliptic pulp (500mg / kg BW) group I Ⅱ Ⅲ Ⅳ Ⅴ Ⅵ Ⅶ Tumor volume (mg) 0 364.9 ± 32.4 155.8 ± 12.8 ^## 175.5 ± 13.1 ^# 190 ± 21.0 ^# 115.2 ± 19.8 ^## 103.7 ± 14.9 ^## Tumor growth inhibition rate (%) 0 0 57.3 51.9 47.9 68.4 71.6 BW: body weight #P; <0.0005, ## P; <0.00005 means significant tumor volume compared with CT-26 colorectal cancer cells subcutaneously = (length × width ² ) / 2

Experimental Example  3. CT-26 cells injected with mouse colon cancer cell line In mice On cisplatin  Inhibitory Effect of Peach Extract on Hepatic and Renal Toxicity Induced by

The experiment of Experimental Example 2 confirmed that the anti-cancer efficacy of the peach extract and when combined with cisplatin increased the anti-cancer efficacy of cisplatin and sacrificed mice. Blood was collected from the mice, liver and kidney tissues were extracted, and liver and kidney toxicity were examined using the method described in Experimental Example 1.

As shown in Table 6, the liver weight was decreased when cisplatin was administered to the mice injected with CT-26 colorectal cancer cells, but the weight of the liver was not reduced in the peach extract administration group, but the cisplatin in the cisplatin and peach extract administration group. The weight of the liver, which had been reduced, was restored to normal level (see FIG. 3 and Table 6).

CT-26 mouse colon cancer cells were injected with cisplatin and blood nitric oxide production and amino group transfer enzymes, AST and ALT, and lipid peroxides, MDA, were increased. No increase in the indicators was observed, and the increase of these indicators by cisplatin was significantly suppressed in the cisplatin and peach extract groups.

GSH, which plays an important role in the detoxification of toxic substances, was also significantly depleted in the cisplatin-administered group, but no depletion was observed in the peach extract-administered group, whereas the depletion of GSH by cisplatin was inhibited in the cisplatin and peach extract-administered groups (see Table 6).

Protective Effect of Peach Extract on Cisplatin-induced Liver Toxicity in White Mice (BALB / c Mice) Control CT-26 cell subcutaneous injection group CT-26 Cell Subcutaneous Injection Cisplatin (5mg / kg BW) White peach pulp (500mg / kg BW) Ecliptic pulp (500mg / kg BW) Cisplatin (5mg / kg) White peach pulp (500mg / kg BW) Ecliptic pulp (500mg / kg BW) group I Ⅱ Ⅲ Ⅳ Ⅴ Ⅵ Ⅶ L.W / BW (%) 8.3 ± 0.3 8.1 ± 0.2 6.6 ± 0.2 ^# 8.0 ± 0.2 7.9 ± 0.3 8.0 ± 0.6 ^* 7.9 ± 0.5 ^* Nitric Oxide (μM) 11.0 ± 1.4 21.9 ± 1.1 ^※※※ 104.4 ± 3.7 ^### 23.8 ± 1.1 22.5 ± 1.7 61.0 ± 4.2 ^** 53.2 ± 1.9 ^** AST (U / L) 75.7 ± 0.5 80.4 ± 1.0 ^※※ 280.1 ± 3.3 ^### 77.6 ± 1.8 74.5 ± 4.1 105.0 ± 2.8 ^*** 95.9 ± 7.6 ^** ALT (U / L) 123.9 ± 0.4 156.5 ± 3.9 ^※※ 232.1 ± 7.5 ^## 146.4 ± 8.9 142.8 ± 39.2 158.1 ± 7.0 ^* 153.6 ± 6.7 ^* MDA (nmol / mg) 3.2 ± 0.2 4.9 ± 0.2 ^※※※ 17.0 ± 0.7 ^### 4.2 ± 0.8 5.8 ± 0.5 5.9 ± 1.0 ^** 4.1 ± 0.5 ^** GSH (nmol / mg) 23.1 ± 0.4 21.4 ± 0.4 ^※ 11.9 ± 0.3 ^### 21.6 ± 0.5 21.8 ± 0.1 20.4 ± 0.5 ^** 19.9 ± 1.9 ^** L.W (liver weight) / BW (body weight): Percentage of liver tissue weight to mouse weight ※ P; <0.05, * P; <0.005, ※※※ P; <0.0005 was significant #P with control; <0.05, ## P; <0.005, ### P; <0.00001 indicates significance * P with the subcutaneous injection group of CT-26 cells; <0.05, ** P; <0.0005, *** P; <0.00001 was significantly different from cisplatin-only group after CT-26 cell subcutaneous injection.

 Kidney weight decreased when cisplatin was administered to mice injected with CT-26 colorectal cancer cells, but the weight of kidney was not decreased in peach extract group, but was reduced by cisplatin in group treated with cisplatin and peach extract. The weight of the was restored to almost normal level (see FIG. 3 and Table 7). Blood urea nitrogen and creatinine, which are indicators of renal toxicity, were significantly increased in the cisplatin-treated group, but similar to the control group in the peach extract group. (See Table 7).

Protective Effect of Peach Extract on Cisplatin-induced Kidney Toxicity in White Mice (BALB / c Mice) Control CT-26 cell subcutaneous injection group CT-26 Cell Subcutaneous Injection Cisplatin (5mg / kg BW) White peach pulp (500mg / kg BW) Ecliptic pulp (500mg / kg BW) Cisplatin (5mg / kg) White peach pulp (500mg / kg BW) Ecliptic pulp (500mg / kg BW) group I Ⅱ Ⅲ Ⅳ Ⅴ Ⅵ Ⅶ K.W / BW (%) 2.7 ± 0.2 2.7 ± 0.1 1.8 ± 0.03 ^### 2.3 ± 0.1 2.2 ± 0.1 2.1 ± 0.1 ^*** 2.1 ± 0.1 ^** BUN (mg / ㎗) 15.1 ± 0.4 17.1 ± 0.6 ^* 25.1 ± 0.7 ^## 15.3 ± 0.3 15.2 ± 0.3 19.8 ± 0.4 ^* 18.5 ± 0.2 ^* Creatinine (mg / dl) 1.5 ± 0.1 2.3 ± 0.2 ^※※ 6.0 ± 0.2 ^## 2.5 ± 0.1 2.3 ± 0.2 3.4 ± 0.1 ^** 3.0 ± 0.3 ^** MDA (nmol / mg) 8.2 ± 1.4 8.7 ± 0.9 29.9 ± 3.3 ^# 10.6 ± 1.2 9.4 ± 1.0 15.6 ± 2.8 ^* 14.7 ± 0.7 ^* K.W (renal weight) / BW (body weight): Percentage of kidney tissue weight to mouse weight ※ P; <0.05, * P; <0.005 was significant #P with control; <0.005, ## P; <0.0005, ### P; <0.00001 indicates significance * P with the subcutaneous injection group of CT-26 cells; <0.05, ** P; <0.005, *** P; <0.0005 was significantly different from cisplatin-only group after CT-26 cell subcutaneous injection.

 Taken together, the peach extract was found to be effective in inhibiting the growth of cancer cells as well as improving the anticancer efficacy while reducing the liver and kidney toxicity, which are side effects of cisplatin when administered with cisplatin.

Peach extract is a side effect of anti-cancer treatment when 15 days of low concentration of cisplatin (5mg / kg) is administered to suppress cancer cell growth as well as liver and kidney toxicity caused by 16 hours of high concentration of cisplatin (45mg / kg). It was also confirmed that significantly inhibited liver and kidney toxicity.

It describes a pharmaceutical composition comprising a peach extract of the present invention and a preparation example of a health functional food, but the present invention is not intended to limit it, but only to explain in detail.

Formulation example  One. Powder  Produce

300 mg of peach extract of Example 1

Lactose 100 mg

Talc 10 mg

The above ingredients are mixed and filled in an airtight cloth to prepare a powder.

Formulation example  2. Preparation of Tablets

50 mg of peach extract of Example 1

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

After mixing the above components, tablets are prepared by tableting according to a conventional method for preparing tablets.

Formulation example  3. Manufacture of capsule

50 mg of peach extract of Example 1

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.

Formulation example  4. Preparation of Injectables

50 mg of peach extract of Example 1

Appropriate sterile distilled water for injection

pH adjuster

According to the conventional method for preparing an injection, the amount of the above ingredient is prepared per ampoule (2 ml).

Formulation example  5. Liquid  Produce

1000 mg of peach extract of Example 1

20 g of sugar

20 g of isomerized sugar

Lemon flavor

Purified water was added to adjust the total volume to 1000 ml. According to the conventional method for preparing a liquid, the above components were mixed, and then filled into a brown bottle and sterilized to prepare a liquid.

Formulation example  6. Manufacture of healthy food

1000 mg of peach extract of Example 1

Vitamin mixture proper amount

70 μg of Vitamin A Acetate

Vitamin E 1.0 mg

Vitamin B ₁ 0.13 mg

Vitamin B ₂ 0.15 mg

Vitamin B ₆ 0.5 mg

0.2 μg of vitamin B ₁₂

Vitamin C 10 mg

10 μg biotin

Nicotinic Acid 1.7 mg

Folate 50 ㎍

Calcium Pantothenate 0.5mg

Mineral mixture

Ferrous Sulfate 1.75 mg

Zinc Oxide 0.82 mg

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Dibasic calcium phosphate 55 mg

Potassium Citrate 90 mg

Calcium Carbonate 100 mg

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method. The granules may be prepared and used for preparing a health food composition according to a conventional method.

Formulation example  7. Manufacture of health drinks

1000 mg of peach extract of Example 1

Citric acid 1000 mg

100 g oligosaccharides

Plum concentrate 2 g

1 g of taurine

Add 900 ml of purified water

After mixing the above components according to the conventional healthy beverage production method, and then stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and then refrigerated and stored Used to prepare the healthy beverage composition of the invention.

 As described above, the composition containing the peach extract of the present invention as an active ingredient not only has inhibitory activity against hepatotoxicity and kidney toxicity induced by an anticancer agent, but also when the peach extract is administered only, tumor growth similar to cisplatin is an anticancer agent. It showed inhibitory effect, and when used in combination with an anticancer agent, confirms that it enhances the anticancer efficacy of the anticancer agent, and thus can be used as a pharmaceutical composition or health functional food for the prevention and treatment of liver and renal toxic diseases caused by the anticancer agent. .

Claims (5)

Pharmaceutical composition for the prevention and treatment of liver toxicity and kidney toxicity diseases caused by an anticancer agent comprising a peach extract as an active ingredient.        The pharmaceutical composition of claim 1, wherein the peach is white or zodiacal.        The pharmaceutical composition according to claim 1, wherein the extract is an extract soluble in a solvent selected from a lower alcohol such as water, methanol, ethanol or a mixed solvent thereof.        An anticancer adjuvant comprising a peach extract having an inhibitory activity against liver and kidney toxicity induced by an anticancer agent as an active ingredient.        Health functional food for the prevention and improvement of liver and kidney toxic diseases caused by anticancer agents, including peach extract as an active ingredient.

Images